Sysmex (OTCMKTS:SSMXY) Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis. In coagulation testing, Sysmex provides instruments and reagents to assess blood‐clotting function and monitor anticoagulant therapy. Its urine analyzers combine digital imaging with automated particle analysis, while immunochemistry systems enable quantitative measurement of biomarkers for infectious disease, hemostasis and diabetes monitoring.
Sysmex maintains a global footprint with regional headquarters and sales subsidiaries in North America, Europe, Asia‐Pacific, Latin America and Africa. Its products and services reach more than 150 countries, supported by local service networks that offer training, maintenance and technical support. The company collaborates with academic and industrial partners to develop molecular diagnostic assays and next‐generation testing platforms, positioning itself at the forefront of personalized medicine and digital health solutions.
Founded in 1968, Sysmex has grown through continuous investment in research and development. The company is led by President and Chief Executive Officer Yutaka Yamada, supported by an executive team focused on innovation, quality and international expansion. Over its history, Sysmex has earned a reputation for reliability and precision in clinical diagnostics, driving efforts to improve patient care and laboratory efficiency worldwide.
